SK154796A3 - Use of rapamycin for the inhibition of neuronal cells necrosis - Google Patents

Use of rapamycin for the inhibition of neuronal cells necrosis Download PDF

Info

Publication number
SK154796A3
SK154796A3 SK1547-96A SK154796A SK154796A3 SK 154796 A3 SK154796 A3 SK 154796A3 SK 154796 A SK154796 A SK 154796A SK 154796 A3 SK154796 A3 SK 154796A3
Authority
SK
Slovakia
Prior art keywords
rapamycin
nmda
compound
adduct
diels
Prior art date
Application number
SK1547-96A
Other languages
English (en)
Slovak (sk)
Inventor
Stephen Shi-Hsun Lin
Katherine Lu Molnar-Kimber
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of SK154796A3 publication Critical patent/SK154796A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1547-96A 1995-12-07 1996-12-04 Use of rapamycin for the inhibition of neuronal cells necrosis SK154796A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US833795P 1995-12-07 1995-12-07

Publications (1)

Publication Number Publication Date
SK154796A3 true SK154796A3 (en) 1997-09-10

Family

ID=21731060

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1547-96A SK154796A3 (en) 1995-12-07 1996-12-04 Use of rapamycin for the inhibition of neuronal cells necrosis

Country Status (23)

Country Link
EP (1) EP0778023B1 (ja)
JP (1) JPH09183727A (ja)
KR (1) KR970032856A (ja)
CN (1) CN1112925C (ja)
AR (1) AR008747A1 (ja)
AT (1) ATE234095T1 (ja)
AU (1) AU700653B2 (ja)
BR (1) BR9605895A (ja)
CA (1) CA2192298A1 (ja)
CZ (2) CZ6498A3 (ja)
DE (1) DE69626610T2 (ja)
DK (1) DK0778023T3 (ja)
ES (1) ES2188730T3 (ja)
HU (1) HUP9603370A3 (ja)
IL (1) IL119778A (ja)
MX (1) MX9606131A (ja)
NO (1) NO309966B1 (ja)
NZ (1) NZ299888A (ja)
PT (1) PT778023E (ja)
SI (1) SI0778023T1 (ja)
SK (1) SK154796A3 (ja)
TW (1) TW427904B (ja)
ZA (1) ZA9610245B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
WO2001079177A1 (en) * 2000-04-17 2001-10-25 Gpi Nil Holdings, Inc. Cyclic diaza compounds for treating neurodegenerative disorders
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
WO2004091633A1 (en) * 2003-04-09 2004-10-28 Wyeth Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof
DE602004029146D1 (de) 2003-04-09 2010-10-28 Wyeth Llc Derivate von 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkylphosphonsäure und deren verwendung als n-methyl-d-aspartat- (nmda-) rezeptorantagonisten
WO2004089369A2 (en) * 2003-04-11 2004-10-21 Cambridge University Technical Services Limited Methods and means for treating protein conformational disorders
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
GT200400213A (es) 2003-10-22 2007-09-05 Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
BRPI0519495A2 (pt) 2004-12-20 2009-02-03 Wyeth Corp composto ou um sal farmaceuticamente aceitÁvel do mesmo, uso de um composto, e, mÉtodo para preparar um composto
KR20070090931A (ko) 2004-12-20 2007-09-06 와이어쓰 라파마이신 유도체 및 신경계장애의 치료에서의 그의 용도
JP4857071B2 (ja) * 2006-10-12 2012-01-18 潤平 笹部 筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
BRPI1010655A2 (pt) * 2009-04-10 2019-09-03 Qi Haiyan novos agentes antienvelhecimento e métodos para identificá-los
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
CA2768710A1 (en) * 2009-07-24 2011-01-27 Institut National De La Recherche Scientifique Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US9121859B2 (en) 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
CN113209101A (zh) 2013-06-05 2021-08-06 法奈克斯公司 用于组合的活性药物成分的稳定口服溶液
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
JP2021502971A (ja) * 2017-11-15 2021-02-04 ヴァンダービルト ユニヴァーシティ リソソーム機能の改善および神経変性疾患の治療のための方法および組成物
CN114366738A (zh) * 2021-12-20 2022-04-19 中国人民解放军军事科学院军事医学研究院 雷帕霉素在促进神经干细胞扩增中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
IL101353A0 (en) * 1991-04-03 1992-11-15 American Home Prod Pharmaceutical compositions for treating diabetes
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5260299A (en) * 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
KR970032856A (ko) 1997-07-22
HU9603370D0 (en) 1997-01-28
CN1112925C (zh) 2003-07-02
DE69626610D1 (de) 2003-04-17
NZ299888A (en) 2001-02-23
ES2188730T3 (es) 2003-07-01
CZ354496A3 (cs) 1998-03-18
AR008747A1 (es) 2000-02-23
EP0778023A1 (en) 1997-06-11
BR9605895A (pt) 1998-08-18
MX9606131A (es) 1997-08-30
DK0778023T3 (da) 2003-06-30
PT778023E (pt) 2003-06-30
ATE234095T1 (de) 2003-03-15
CN1159915A (zh) 1997-09-24
IL119778A0 (en) 1997-03-18
CZ6498A3 (cs) 1998-06-17
AU700653B2 (en) 1999-01-14
ZA9610245B (en) 1998-06-05
TW427904B (en) 2001-04-01
SI0778023T1 (en) 2003-08-31
CA2192298A1 (en) 1997-06-08
HUP9603370A2 (en) 1997-05-28
IL119778A (en) 1999-07-14
DE69626610T2 (de) 2003-10-02
JPH09183727A (ja) 1997-07-15
AU7417896A (en) 1997-06-12
EP0778023B1 (en) 2003-03-12
HUP9603370A3 (en) 1998-12-28
NO965238L (no) 1997-06-09
NO309966B1 (no) 2001-04-30
NO965238D0 (no) 1996-12-06

Similar Documents

Publication Publication Date Title
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
KR102014883B1 (ko) 근위축성 측삭 경화증 치료용 신규 조성물
MXPA96006131A (en) Neuroprotect agents
Beal et al. Systemic approaches to modifying quinolinic acid striatal lesions in rats
JP2003535034A (ja) ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
US20070190043A1 (en) Use of a topical medicament comprising riluzole
EP0485431B1 (en) Partial agonists of the strychnine insensitive glycine modulatory site of the n-methyl-d-aspartate receptor complex as neuropsychopharmacological agents
JP2017534673A (ja) 精神病性障害を治療するための方法および組成物
AU2011285611B2 (en) Inhibitors of ERK for developmental disorders of neuronal connectivity
WO1999051223A1 (en) Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
EP3746057B1 (en) Dapansutrile for preventing or treating alzheimer's disease
Schorderet Alzheimer's disease: fundamental and therapeutic aspects
DE69824165T2 (de) Verwendung von chelerythrin und strahlung in der tumortherapie
US20080207697A1 (en) Use of Epothilones in the Treatment of Neuronal Connectivity Defects Such as Schizophrenia and Autism
EP2874617B1 (en) Baclofen and acamprosate based therapy of macular degeneration disorders
US20230390223A1 (en) Administration of antipurinergic compositions for treating nervous system disorders
US8664237B2 (en) Spiperone derivatives and methods of treating disorders
WO2004096222A1 (en) Use of 1-(5-isoquinolinesulfonyl)homopiperazine, its active metabolites, isomers and salts for treating and preventing hypopigmentary disorders
US20090221610A1 (en) Compositions and Methods for Treating Cognitive Disorders
US20080287405A1 (en) Compositions and Methods Relating to Protein Kinase Inhibitors
JP2015500805A (ja) 認知強化方法
EP1471901B1 (en) Spermidine derivative for the treatment of chronic neurodegenerative diseases
EP1408944B1 (en) Erucamide compounds for the treatment and prevention of disturbances of the secretory system
WO2002072025A2 (en) Improving postsynaptic response by a combination of 4-minopyridine and agonist
IL302223A (en) Intranasal administration of suramin for the treatment of nervous system disorders